Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings.
Armenia D, Bouba Y, Gagliardini R, Gori C, Bertoli A, Borghi V, Gennari W, Micheli V, Callegaro AP, Gazzola L, Bruzzone B, Giannetti A, Mazzotta V, Vergori A, Mastrorosa I, Colafigli M, Lichtner M, di Biagio A, Maggiolo F, Rizzardini G, d'Arminio Monforte A, Andreoni M, Mussini C, Antinori A, Ceccherini-Silberstein F, Perno CF, Santoro MM; Italian INI-Surveillance Group. Armenia D, et al. Among authors: gagliardini r. J Clin Virol. 2020 Sep;130:104534. doi: 10.1016/j.jcv.2020.104534. Epub 2020 Jul 11. J Clin Virol. 2020. PMID: 32769022 Free article.
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study.
Gagliardini R, Rossetti B, Bianco C, Rusconi S, Colafigli M, Prinapori R, Francisci D, Fantauzzi A, Orofino G, Vignale F, Di Giambenedetto S, De Luca A. Gagliardini R, et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19818. doi: 10.7448/IAS.17.4.19818. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397562 Free PMC article.
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.
Mondi A, Fabbiani M, Ciccarelli N, Colafigli M, D'Avino A, Borghetti A, Gagliardini R, Cauda R, De Luca A, Di Giambenedetto S. Mondi A, et al. Among authors: gagliardini r. J Antimicrob Chemother. 2015;70(6):1843-9. doi: 10.1093/jac/dkv037. Epub 2015 Feb 26. J Antimicrob Chemother. 2015. PMID: 25885326
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE).
Milanini B, Ciccarelli N, Fabbiani M, Baldonero E, Limiti S, Gagliardini R, Borghetti A, D'Avino A, Mondi A, Colafigli M, Cauda R, Di Giambenedetto S. Milanini B, et al. Among authors: gagliardini r. Clin Neuropsychol. 2016 Jan-Dec;30(sup1):1457-1468. doi: 10.1080/13854046.2016.1183048. Epub 2016 May 16. Clin Neuropsychol. 2016. PMID: 27180611
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study.
Focà E, Fabbiani M, Prosperi M, Quiros Roldan E, Castelli F, Maggiolo F, Di Filippo E, Di Giambenedetto S, Gagliardini R, Saracino A, Di Pietro M, Gori A, Sighinolfi L, Pan A, Postorino MC, Torti C; Italian MASTER Cohort. Focà E, et al. Among authors: gagliardini r. Medicine (Baltimore). 2016 Jul;95(29):e4091. doi: 10.1097/MD.0000000000004091. Medicine (Baltimore). 2016. PMID: 27442636 Free PMC article.
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study.
Quiros-Roldan E, Raffetti E, Castelli F, Focà E, Castelnuovo F, Di Pietro M, Gagliardini R, Gori A, Saracino A, Fornabaio C, Sighinolfi L, Di Filippo E, Maggiolo F, Donato F. Quiros-Roldan E, et al. Among authors: gagliardini r. J Antimicrob Chemother. 2016 Dec;71(12):3519-3527. doi: 10.1093/jac/dkw307. Epub 2016 Aug 19. J Antimicrob Chemother. 2016. PMID: 27543658
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir.
Gagliardini R, Bandera A, Zaccarelli M, Sterrantino G, Latini A, D'Avino A, Lapadula G, Antinori A, Cauda R, De Luca A, Gori A, Di Giambenedetto S, Fabbiani M. Gagliardini R, et al. Antivir Ther. 2018;23(2):139-148. doi: 10.3851/IMP3188. Antivir Ther. 2018. PMID: 28799920
137 results